Literature DB >> 21900914

Paraoxonase-1 and clopidogrel efficacy.

Patrick M Dansette, Julien Rosi, Gildas Bertho, Daniel Mansuy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21900914     DOI： 10.1038/nm.2436

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  9 in total

Review 1.  Sulfenic acids as reactive intermediates in xenobiotic metabolism.

Authors:  Daniel Mansuy; Patrick M Dansette
Journal:  Arch Biochem Biophys       Date:  2010-10-01       Impact factor: 4.013

2.  Paraoxonase-1 is a major determinant of clopidogrel efficacy.

Authors:  Heleen J Bouman; Edgar Schömig; Jochem W van Werkum; Janna Velder; Christian M Hackeng; Christoph Hirschhäuser; Christopher Waldmann; Hans-Günther Schmalz; Jurriën M ten Berg; Dirk Taubert
Journal:  Nat Med       Date:  2010-12-19       Impact factor: 53.440

3.  Structure and stereochemistry of the active metabolite of clopidogrel.

Authors:  Jean-Marie Pereillo; Mohamed Maftouh; Alain Andrieu; Marie-Francoise Uzabiaga; Olivier Fedeli; Pierre Savi; Marc Pascal; Jean-Marc Herbert; Jean-Pierre Maffrand; Claudine Picard
Journal:  Drug Metab Dispos       Date:  2002-11       Impact factor: 3.922

4.  An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma.

Authors:  Gilles Tuffal; Sebastien Roy; Melanie Lavisse; Denis Brasseur; Joe Schofield; Nathalie Delesque Touchard; Pierre Savi; Nicolas Bremond; Marie-Claude Rouchon; Fabrice Hurbin; Eric Sultan
Journal:  Thromb Haemost       Date:  2011-02-08       Impact factor: 5.249

5.  Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters.

Authors:  S Billecke; D Draganov; R Counsell; P Stetson; C Watson; C Hsu; B N La Du
Journal:  Drug Metab Dispos       Date:  2000-11       Impact factor: 3.922

6.  No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.

Authors:  Dirk Sibbing; Werner Koch; Steffen Massberg; Robert A Byrne; Julinda Mehilli; Stefanie Schulz; Katharina Mayer; Isabell Bernlochner; Albert Schömig; Adnan Kastrati
Journal:  Eur Heart J       Date:  2011-04-28       Impact factor: 29.983

7.  Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel.

Authors:  Patrick M Dansette; Julie Libraire; Gildas Bertho; Daniel Mansuy
Journal:  Chem Res Toxicol       Date:  2009-02       Impact factor: 3.739

8.  Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS.

Authors:  Makoto Takahashi; Henrianna Pang; Kiyoshi Kawabata; Nagy A Farid; Atsushi Kurihara
Journal:  J Pharm Biomed Anal       Date:  2008-08-23       Impact factor: 3.935

9.  Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.

Authors:  Miho Kazui; Yumi Nishiya; Tomoko Ishizuka; Katsunobu Hagihara; Nagy A Farid; Osamu Okazaki; Toshihiko Ikeda; Atsushi Kurihara
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922
  9 in total
  13 in total

Review 1.  Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.

Authors:  Daniel Seung Kim; Judit Marsillach; Clement E Furlong; Gail P Jarvik
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

Review 2.  Genetics of platelet inhibitor treatment.

Authors:  Dietmar Trenk; Willibald Hochholzer
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 3.  Paraoxonases: metabolic role and pharmacological projection.

Authors:  Carlos Moya; Salvador Máñez
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-02-06       Impact factor: 3.000

4.  The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro.

Authors:  V Ancrenaz; J Desmeules; R James; P Fontana; J-L Reny; P Dayer; Y Daali
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 5.  Recent advances in the pharmacogenetics of clopidogrel.

Authors:  Thomas Cuisset; Pierre-Emmanuel Morange; Marie-Christine Alessi
Journal:  Hum Genet       Date:  2011-12-30       Impact factor: 4.132

6.  The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.

Authors:  Ho-Sook Kim; Younghae Lim; Minkyung Oh; Jong-Lyul Ghim; Eun-Young Kim; Dong-Hyun Kim; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2015-12-28       Impact factor: 4.335

7.  Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.

Authors:  Yaoqiu Zhu; Jiang Zhou
Journal:  ACS Med Chem Lett       Date:  2012-09-09       Impact factor: 4.345

8.  PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Michael Man; Suman Duvvuru; Joseph R Walker; Scott S Sundseth; Jean-Philippe Collet; Jessica T Delaney; Jean-Sebastien Hulot; Sabina A Murphy; Guillaume Paré; Matthew J Price; Dirk Sibbing; Tabassome Simon; Dietmar Trenk; Elliott M Antman; Marc S Sabatine
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

Review 9.  Cytochrome P450-activated prodrugs.

Authors:  Paul R Ortiz de Montellano
Journal:  Future Med Chem       Date:  2013-02       Impact factor: 3.808

10.  Formation of the thiol conjugates and active metabolite of clopidogrel by human liver microsomes.

Authors:  Haoming Zhang; Wei C Lau; Paul F Hollenberg
Journal:  Mol Pharmacol       Date:  2012-05-14       Impact factor: 4.436
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.